Biogen Inc. $BIIB Stock Position Raised by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. raised its position in Biogen Inc. (NASDAQ:BIIB) by 1,162.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 125,959 shares of the biotechnology company’s stock after buying an additional 115,979 shares during the period. Crossmark Global Holdings Inc.’s holdings in Biogen were worth $28,452,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of BIIB. Albion Financial Group UT boosted its stake in shares of Biogen by 2,833.3% in the third quarter. Albion Financial Group UT now owns 176 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 170 shares during the last quarter. Carnegie Investment Counsel purchased a new stake in shares of Biogen during the third quarter worth approximately $369,000. Integrated Advisors Network LLC raised its stake in Biogen by 3.5% in the 3rd quarter. Integrated Advisors Network LLC now owns 1,403 shares of the biotechnology company’s stock valued at $317,000 after purchasing an additional 48 shares during the last quarter. Bank Pictet & Cie Europe AG raised its stake in Biogen by 5.7% in the 3rd quarter. Bank Pictet & Cie Europe AG now owns 3,279 shares of the biotechnology company’s stock valued at $741,000 after purchasing an additional 176 shares during the last quarter. Finally, Prime Capital Investment Advisors LLC lifted its holdings in Biogen by 776.4% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 21,271 shares of the biotechnology company’s stock valued at $4,805,000 after purchasing an additional 18,844 shares in the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Trading Down 0.9%

Shares of Biogen stock opened at $240.98 on Thursday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The stock’s 50 day simple moving average is $221.92 and its 200-day simple moving average is $205.19. The stock has a market cap of $35.60 billion, a P/E ratio of 17.40, a P/E/G ratio of 2.71 and a beta of 0.09. Biogen Inc. has a 1-year low of $138.00 and a 1-year high of $244.65.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The firm had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.46 billion. During the same quarter last year, the firm earned $5.47 earnings per share. The business’s revenue for the quarter was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Analysts predict that Biogen Inc. will post 12.31 EPS for the current fiscal year.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Positive kidney-disease data: Biogen highlighted 76-week EMPAVELI data showing sustained proteinuria reduction, stable kidney function and a consistent safety profile in C3G and primary IC-MPGN. Additional felzartamab and nephrology programs strengthened investor confidence in the company’s expanding renal franchise. Biogen nephrology data announcement
• Positive Sentiment: Higher analyst price target: Wells Fargo raised its BIIB target from $250 to $310 and maintained an “overweight” rating, signaling significant potential upside based on the company’s pipeline and growth prospects.
• Positive Sentiment: Earnings optimism: Zacks expects Biogen to beat consensus estimates in its upcoming third-quarter report, citing favorable earnings and revenue trends. The company is scheduled to report on October 28, making the release a near-term catalyst. Biogen earnings preview
• Positive Sentiment: Pipeline and strategic-growth expectations: Biogen is being featured among biotechnology companies with promising late-stage drug programs and upcoming regulatory or clinical milestones. The Apellis transaction is also expected to become increasingly accretive to adjusted earnings beginning in 2027. Zacks biotech pipeline commentary

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Barclays lifted their target price on shares of Biogen from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 29th. Wedbush upped their target price on shares of Biogen from $201.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, July 30th. Zacks Research upgraded shares of Biogen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. HC Wainwright increased their target price on shares of Biogen from $237.00 to $251.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Finally, HSBC raised their price target on shares of Biogen from $165.00 to $175.00 and gave the stock a “reduce” rating in a research note on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $240.86.

Biogen Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.